×
About 350 results

ALLMedicine™ Papillary Tumors Center

Research & Reviews  112 results

"Papillary Adenoma-like" Renal Tumor with TFE3 Gene Rearrangement, A Potential Precurso...
https://doi.org/10.1177/10668969221108747
International Journal of Surgical Pathology; Algarrahi K, Omoscharka E et. al.

Jul 20th, 2022 - MiT family translocation renal cell carcinomas harbor gene fusion involving members of MiT family of transcription factors. Their precursor lesions have not been identified. Herein, we report the first case of small papillary tumors morphologicall...

Pediatric pineal region tumors: institutional experience of surgical managements with p...
https://doi.org/10.1007/s00381-022-05595-4
Child's Nervous System : ChNS : Official Journal of the I... Tomita T, Alden TD et. al.

Jul 14th, 2022 - Resecting pineal region tumors in children is often challenging. Several approaches have been proposed and practiced. A personal series of pediatric pineal region tumors resected through craniotomy with posterior interhemispheric occipital transte...

Genetic profile identification and clinicopathologic characteristics analysis of the th...
https://doi.org/10.1016/j.prp.2022.153980
Pathology, Research and Practice; Wang T, Liu X et. al.

Jun 28th, 2022 - Thyroid-like low-grade nasopharyngeal papillary adenocarcinoma (TL-LGNPPA) is an extremely rare malignancy bearing histomorphological similarities to papillary thyroid carcinoma with good prognosis. It's important to distinguish TL-LGNPPA from oth...

Papillary Thyroid Carcinoma
http://emedicine.medscape.com/article/282276-overview

Jun 14th, 2022 - Practice Essentials Papillary thyroid carcinoma (PTC) is the most common form of well-differentiated thyroid cancer, and the most common form of thyroid cancer to result from exposure to radiation. Papillary carcinoma appears as an irregular solid...

Papillary Thyroid Carcinoma
https://emedicine.medscape.com/article/282276-print

Jun 14th, 2022 - Practice Essentials Papillary thyroid carcinoma (PTC) is the most common form of well-differentiated thyroid cancer, and the most common form of thyroid cancer to result from exposure to radiation. Papillary carcinoma appears as an irregular solid...

see more →

Drugs  2 results see all →

Clinicaltrials.gov  5 results

Axitinib +/- Pembrolizumab in First Line Treatment of mPRCC
https://clinicaltrials.gov/ct2/show/NCT05096390

Oct 27th, 2021 - Papillary renal cell carcinoma (PRCC) is the second most common subtype of renal carcinoma accounting for approximatively 10-15% of all renal cancers. Different types of PRCC have been described on the basis of two histologic subtypes, type 1 in 2...

Mitomycin C Intravesical Chemotherapy in Conjunction With Synergo® Radiofrequency-Induced Hyperthermia for Treatment of Carcinoma in Situ Non-Muscle Invasive Bladder Cancer Patients Unresponsive to...
https://clinicaltrials.gov/ct2/show/NCT03335059

Apr 15th, 2020 - This study will determine whether Synergo® RITE + MMC treatment is efficacious as second-line therapy for CIS NMIBC BCG-unresponsive patients with or without papillary NMIBC, through examination of the complete response rate (CRR) and disease-free...

Study to Improve Detection and Early Recurrence Rate in Bladder Cancer Patients Using Hexvix Fluorescence Cystoscopy
https://clinicaltrials.gov/ct2/show/NCT00233402

Oct 11th, 2013 - In superficial bladder cancer macroscopic tumors including non-invasive papillary tumors (Ta) in the bladder are relatively easy to visualize by cystoscopic examination under white light. However, dysplasia, carcinoma in situ (CIS) or small exophy...

Surgery and BCG in Treating Patients With Bladder Cancer
https://clinicaltrials.gov/ct2/show/NCT00002990

Jun 12th, 2013 - OBJECTIVES: Demonstrate that after complete transurethral resection of all papillary tumors, one third dose BCG (Bacillus Calmette-Guerin vaccine; OncoTICE) is equivalent to full dose BCG and short term maintenance is equivalent to long term maint...

Prophylactic Pancreatic Duct Stent Placement After ESP of Major Papillary Tumors; Prospective, Randomized Study
https://clinicaltrials.gov/ct2/show/NCT01737463

Dec 4th, 2012 - The patient was adequately sedated by intravenous administration of midazolam with or without meperidine. ESP and pancreatic duct stent insertion were undertaken using two methods: conventional and wire-guieded ESP. The conventional ESP method was...

see more →

News  21 results

Radioactive Iodine Shows No Benefit in Low-Risk Thyroid Cancer
https://www.medscape.com/viewarticle/969969

Mar 9th, 2022 - Patients with low-risk differentiated thyroid cancer (DTC) undergoing thyroidectomy show no improvements in outcomes with the use of postoperative radioiodine ablation compared to those who do not receive this therapy, suggesting these patients ca...

N-803 Plus Intravesical BCG Produces 57% DFS in BCG-Unresponsive Papillary Bladder Cancer
https://www.onclive.com/view/n-803-plus-intravesical-bcg-produces-57-dfs-in-bcg-unresponsive-papillary-bladder-cancer

Mar 1st, 2022 - Intravesical Bacillus Calmette–Guérin (BCG) in combination with N-803 (Anktiva) resulted in a 12-month disease-free survival (DFS) rate of 57% in patients with BCG-unresponsive high-grade papillary non–muscle invasive bladder cancer (NMIBC), meeti...

Expert Highlights Shifting Management of Localized Bladder Cancer
https://www.onclive.com/view/expert-highlights-shifting-management-of-localized-bladder-cancer

Oct 6th, 2021 - John P. Sfakianos, MD Treatment options for patients with localized bladder cancer, beyond Bacillus Calmette-Guérin (BCG), are evolving as immunotherapies and novel agents are gaining traction in the management of this population, according to Jo...

FDA Approvals in Urothelial Cancer and Prostate Cancer, Priority Review in CRC, and More
https://www.onclive.com/view/fda-approvals-in-urothelial-cancer-and-prostate-cancer-priority-review-in-crc-and-more

Apr 2nd, 2021 - Today- FDA approvals in urothelial cancer and prostate cancer, priority review designations in colorectal cancer and urothelial cancer, breakthrough designations in breast cancer and myelodysplastic syndromes, and ODAC hearing decisions in sarc...

Merck to Build New Facility to Meet BCG Demand
https://www.onclive.com/view/merck-to-build-new-facility-to-meet-bcg-demand

Dec 20th, 2020 - Merck is set to build a new manufacturing facility to increase its production of TICE Bacillus Calmette–Guérin (BCG), which is currently indicated for the treatment and prophylaxis of patients with carcinoma in situ of the urinary bladder and for ...

see more →